TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The American Geriatrics Society has published a case-based framework to help clinicians assess obesity medications for older adults. It calls for attention to frailty, muscle loss, nutrition, hydration and cognitive and functional status, alongside supports such as resistance training and adequate protein.
The American Geriatrics Society (AGS) has released a clinical framework for prescribing obesity medications to older adults, outlining assessments and supportive care intended to help clinicians weigh treatment against age-related risks. The paper focuses on incretin therapies, including GLP-1 medications, and applies the AGS Geriatrics 5Ms Framework to patient-centered decisions.
Published in the Journal of the American Geriatrics Society, the paper is organized around clinical cases and was developed by the AGS Healthy Aging Special Interest Group. Its authors discuss how clinicians can consider obesity medications in older patients while accounting for differences in health, function and priorities. The report says older adults are underrepresented in clinical trials of these medicines, leaving less evidence specific to this population.
The framework asks clinicians to assess functional status, nutritional adequacy and cognitive impairment before treatment. It also highlights possible concerns including frailty, sarcopenia, loss of lean muscle, malnutrition and dehydration. The paper describes these as factors to consider when evaluating treatment, rather than asserting that every older person taking such medication will experience them.
The 5Ms are Mind, Mobility, Medications, Multicomplexity and Matters Most. The paper recommends pairing medication treatment with supportive measures, including resistance training and adequate dietary protein. Depending on an individual’s needs, care may involve a registered dietitian, physical therapist, fitness trainer or behavioral health professional.
Balancing Weight Treatment With Function
The framework matters because decisions about weight management in older adults may involve goals beyond a number on the scale. Mobility, muscle strength, nutrition and personal priorities can shape whether a treatment plan is suitable and how it should be monitored. The AGS approach encourages clinicians to weigh those considerations alongside potential benefits described for obesity medicines, including weight management and glycemic control.
By emphasizing pretreatment assessment and co-interventions, the paper frames prescribing as part of a broader care plan rather than a medication-only decision. That may help clinicians identify when nutritional or functional support is needed and when a team-based approach may be appropriate. The report is a clinical framework, however; the supplied material does not establish that its recommendations have been tested as an intervention or that they produce particular patient outcomes.
Products Worth Considering
BowFlex Results Series SelectTech Adjustable Dumbbells, Pair
Bowflex SelectTech 840 Adjustable Kettlebell
Fitbit Versa Smart Watch – Black Aluminum, One Size (S & L Bands Included)
As an affiliate, we earn on qualifying purchases.
The Geriatrics 5Ms in Prescribing
The AGS framework adapts its established Geriatrics 5Ms to incretin therapy. In this model, Mind covers cognitive considerations; Mobility addresses movement and function; Medications considers treatment in the setting of other medicines; Multicomplexity recognizes interacting health conditions; and Matters Most focuses on what the patient values.
The new paper addresses a setting where evidence has limitations: the source report says older adults have been underrepresented in clinical trials of obesity medications. It does not give trial participation figures or compare the effectiveness or safety of specific drugs in older people. The framework therefore offers a way to structure clinical judgment, not a claim that all medicines or patients carry the same risks.
The paper is titled Obesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient-Centered Prescribing. It was published in 2026 in the Journal of the American Geriatrics Society (DOI: 10.1111/jgs.70769).
“The framework offers a practical approach to prescribing obesity medications to older adults.”
— The American Geriatrics Society framework, as described in the Medical Xpress report
Evidence and Individual Risks
The source material does not report clinical trial results for this framework, quantify the risks it identifies, or specify how often older adults experience muscle loss, malnutrition or dehydration while using these medicines. It also does not give drug-by-drug prescribing rules, doses or a standard monitoring schedule. Those details should not be inferred from the publication summary.
Because older adults have been underrepresented in trials, the degree to which results from broader study populations apply to different older patients remains an evidence question. The framework calls for individualized assessment, but the supplied report does not say how the guidance will affect prescribing patterns or patient outcomes.
Applying the Guidance in Care
The paper provides clinicians with a structure to apply during discussions and assessments; the source does not announce a rollout, implementation deadline or follow-up study. In practice, clinicians can use the 5Ms to review a patient’s function, nutrition, cognition, other medications and goals, then consider whether additional professionals should be involved.
Further evidence on the effects of obesity medications in older adults would help clarify how benefits and risks vary across this population. Until such details are available in the cited material, the framework’s recommendations should be understood as guidance for individualized clinical decision-making, not a blanket instruction to prescribe or avoid a particular medicine.
Key Questions
Who issued the new framework?
The American Geriatrics Society released it. The paper was developed by the AGS Healthy Aging Special Interest Group and published in the Journal of the American Geriatrics Society.
Which medicines does the framework address?
It discusses obesity medications in older adults, including GLP-1 medicines that act through gut-derived hormonal pathways. The supplied report does not provide drug-specific dosing instructions.
What should clinicians assess before treatment?
The framework highlights functional status, nutritional adequacy and cognitive impairment, as well as age-related concerns such as frailty, sarcopenia and dehydration.
What support does the paper recommend alongside medication?
It recommends considering resistance training and adequate dietary protein. Some patients may benefit from a team that includes nutrition, physical therapy, fitness or behavioral health professionals.
Does the framework say older adults should or should not take these medicines?
No. It presents a patient-centered approach to clinical assessment; it is not a blanket recommendation for or against treatment. Decisions depend on individual health factors and goals.
Source: medicalxpress.com
